216 Participants Needed

PARG Inhibitor for Advanced Cancers

Recruiting at 28 trial locations
IC
OK
Overseen ByOktay Kirak, MD, PhD
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial is testing a new drug called IDE161 to see if it is safe and effective for patients with advanced cancers that have specific genetic changes. The drug works by preventing cancer cells from repairing their DNA, which can lead to their death.

Will I have to stop taking my current medications?

The trial requires that you stop taking certain cancer treatments before enrolling. Specifically, you must not have had chemotherapy, radioimmunotherapy, or treatment with therapeutic antibodies within a specified time before joining the trial.

What makes the drug IDE-161 unique for treating advanced cancers?

IDE-161 is a PARG inhibitor, which is different from other treatments like PARP inhibitors, as it targets a different enzyme involved in DNA repair, potentially offering a new approach for treating advanced cancers.12345

What data supports the effectiveness of the drug IDE-161, a PARG inhibitor, for advanced cancers?

Research shows that inhibiting PARG can reduce the spread of colon cancer cells, suggesting potential benefits for other cancers. Additionally, similar drugs called PARP inhibitors have been effective in treating various cancers by targeting DNA repair mechanisms, which might indicate a promising role for PARG inhibitors like IDE-161.14678

Who Is on the Research Team?

DB

Darrin Beaupre, MD,PhD

Principal Investigator

IDEAYA Biosciences

Are You a Good Fit for This Trial?

This trial is for adults over 18 with advanced solid tumors like ovarian, pancreatic, breast, or prostate cancer. Participants must have genetic changes linked to poor DNA repair and have tried at least one standard treatment without success or couldn't tolerate it. People with brain cancer, recent major surgery, ongoing infections, heart issues, or those who've had certain treatments recently can't join.

Inclusion Criteria

My cancer has worsened after at least one standard treatment or I couldn't tolerate the treatment.
My cancer is advanced or has spread but is not a brain tumor.
My cancer has a genetic change linked to DNA repair issues.

Exclusion Criteria

I have a diagnosed brain cancer.
I have not had major surgery in the last 4 weeks.
I haven't had chemotherapy in the last 4 weeks.
See 7 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Monotherapy Dose Escalation

Participants receive IDE161 as a single agent to determine the maximum tolerated dose and recommended dose for expansion

Approximately 2 years

Combination Dose Escalation

Participants receive IDE161 in combination with pembrolizumab to determine the maximum tolerated dose and recommended dose for expansion

Approximately 2 years

Monotherapy Dose Expansion

Further assessment of safety and tolerability of IDE161 monotherapy at the recommended dose for expansion

Approximately 4 years

Combination Dose Expansion

Further assessment of safety and tolerability of IDE161 in combination with pembrolizumab at the recommended dose for expansion

Approximately 4 years

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

  • IDE-161
Trial Overview The study tests the safety and effectiveness of a new drug called IDE161 on patients with specific types of advanced cancers. It aims to see how well participants tolerate this drug and its impact on their cancer.
How Is the Trial Designed?
4Treatment groups
Experimental Treatment
Group I: Module 2 Part 2: Combination Dose Expansion with pembrolizumabExperimental Treatment2 Interventions
Group II: Module 2 Part 1: Combination Dose Escalation with pembrolizumabExperimental Treatment2 Interventions
Group III: Module 1 Part 2: Monotherapy Dose ExpansionExperimental Treatment1 Intervention
Group IV: Module 1 Part 1: Monotherapy Dose EscalationExperimental Treatment1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

IDEAYA Biosciences

Lead Sponsor

Trials
6
Recruited
1,300+

Merck Sharp & Dohme LLC

Industry Sponsor

Trials
4,096
Recruited
5,232,000+
Chirfi Guindo profile image

Chirfi Guindo

Merck Sharp & Dohme LLC

Chief Marketing Officer since 2022

Degree in Engineering from Ecole Centrale de Paris, MBA from New York University Stern School of Business

Robert M. Davis profile image

Robert M. Davis

Merck Sharp & Dohme LLC

Chief Executive Officer since 2021

JD from Northwestern University Pritzker School of Law, MBA from Northwestern University Kellogg Graduate School of Management, Bachelor's in Finance from Miami University

Published Research Related to This Trial

Inhibition of PARG in colon carcinoma cells reduces their ability to invade and migrate, as shown by experiments using RNA interference and a mouse model of liver metastasis.
The suppression of metastatic behavior is linked to the activation of the PI3K/Akt signaling pathway, while also decreasing levels of NF-κB and matrix metalloproteinases (MMP2 and MMP9), indicating a potential therapeutic target for reducing metastasis in colon cancer.
RNA interference of PARG could inhibit the metastatic potency of colon carcinoma cells via PI3-kinase/Akt pathway.Li, Q., Li, M., Wang, YL., et al.[2019]
PARP inhibitors (PARPi) show promise in treating gastrointestinal (GI) cancers, particularly in patients with deficiencies in homologous recombination (HR) DNA repair, similar to their use in other cancer types like breast and ovarian cancers.
Analysis of genomic data from 1744 GI cancer patients suggests that HR status could serve as a predictive biomarker for the efficacy of PARPi, highlighting the potential for personalized treatment strategies in GI malignancies.
Therapeutic Potential of PARP Inhibitors in the Treatment of Gastrointestinal Cancers.Alhusaini, A., Cannon, A., Maher, SG., et al.[2021]
In a Phase II trial involving 27 patients with germline BRCA1/2-mutant high-grade serous ovarian cancer, 63% were able to safely receive a second course of the PARP inhibitor olaparib, indicating its feasibility for retreatment.
While a second course of olaparib was safe, its efficacy was modest, with only 4 patients (15%) maintaining treatment for 6 months or longer, and common side effects included anemia, nausea, and fatigue.
Multi-Maintenance Olaparib Therapy in Relapsed, Germline BRCA1/2-Mutant High-Grade Serous Ovarian Cancer (MOLTO): A Phase II Trial.Morgan, RD., Clamp, AR., White, DJ., et al.[2023]

Citations

RNA interference of PARG could inhibit the metastatic potency of colon carcinoma cells via PI3-kinase/Akt pathway. [2019]
Therapeutic Potential of PARP Inhibitors in the Treatment of Gastrointestinal Cancers. [2021]
Multi-Maintenance Olaparib Therapy in Relapsed, Germline BRCA1/2-Mutant High-Grade Serous Ovarian Cancer (MOLTO): A Phase II Trial. [2023]
Evaluation of maintenance treatment with PARP inhibitors in ovarian carcinoma patients responding to platinum therapy: Use of restricted mean survival time as an index of efficacy. [2022]
Pharmacologic characterization of fluzoparib, a novel poly(ADP-ribose) polymerase inhibitor undergoing clinical trials. [2021]
Perspectives on PARP inhibitors as pharmacotherapeutic strategies for breast cancer. [2022]
Response of Breast Cancer Cells to PARP Inhibitors Is Independent of BRCA Status. [2022]
Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1a/b trial. [2020]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security